Related references
Note: Only part of the references are listed.Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
Joao Sergio Neves et al.
DIABETES OBESITY & METABOLISM (2023)
Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials
Joaeo Sergio Neves et al.
JOURNAL OF CARDIAC FAILURE (2023)
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials
Joao Pedro Ferreira et al.
DIABETES OBESITY & METABOLISM (2023)
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial
Christian T. Ruff et al.
NATURE MEDICINE (2022)
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials
Ana Rita Leite et al.
DIABETES OBESITY & METABOLISM (2022)
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETOLOGIA (2022)
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial
Kelley R. H. Branch et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes
Joao Pedro Ferreira et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes
David M. Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
Mansoor Husain et al.
DIABETES OBESITY & METABOLISM (2020)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
Steven P. Marso et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure The Need for Further Evidence Generation and Practice Guidelines Optimization
Muhammad Shahzeb Khan et al.
CIRCULATION (2020)
Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
Gianluca Iacobellis et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2020)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes Insights From the EXSCEL Trial
Marat Fudim et al.
CIRCULATION (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?
Milton Packer
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
Anders Jorsal et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial
Kenneth B. Margulies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
John J. Lepore et al.
JACC-HEART FAILURE (2016)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program
Ali Vazir et al.
EUROPEAN HEART JOURNAL (2015)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A
CL Antos et al.
CIRCULATION RESEARCH (2001)
Share Paper
